IVAX Diagnostics Inc, a fully integrated global in vitro diagnostics company, announced that its subsidiary, Diamedix Corp, has entered into a three-year OEM agreement with SCIMEDX Corp to market and sell SCIMEDX’s products, on a worldwide basis, under the Diamedix brand.

The OEM agreement expands Diamedix’s suite of products to include 26 additional ELISA (Enzyme-Linked Immunosorbent Assay) test kits and 41 IFA (Immunoflourescence Assays) products manufactured by SCIMEDX, including HHV 6,7,8, West Nile Virus, Dengue, T. Solium and Toxocara. SCIMEDX, headquartered in Denville, NJ, has more than 30 years operating history in the medical diagnostics industry, specializing in IFA, ELISA and automated laboratory platforms, with a focus on autoimmune and infectious diseases.

Charles Struby, PhD, Chief Executive Officer and President of IVAX Diagnostics, said, “With its focus on diagnostics excellence, and its depth of infectious disease and autoimmune products for both ELISA and IFA formats, we believe SCIMEDX is a solid OEM partner for Diamedix. We believe that this agreement strengthens our product line and enables us to bring to market innovative test kits that meet the needs of the marketplace, while also increasing our competitive position. SCIMEDX’s expertise in autoimmunity, virology rickettsiology and parasitology offer a unique menu of assays.”

Thomas Britten, President of SCIMEDX, said, “Diamedix’s strong sales distribution channel will be an important catalyst for us as our suite of infectious disease diagnostic tests are sold in the growing global in vitro diagnostics market. Working with IVAX Diagnostics through its Diamedix subsidiary will provide us the means to distribute our products, under the well-regarded “Diamedix” brand, to the worldwide market.”

Dr Struby concluded, “This is now the third new or expanded distribution or OEM agreement we have signed during the first quarter of 2010, and is aligned with our strategy of continuing to expand our suite of high-quality, reliable products, while expanding our geographical footprint.”

Source:  IVAX Diagnostics